On This Day in Health: July 2, 2024
On July 2, 2024, the U.S. Food and Drug Administration approved Kisunla, the brand name for donanemab-azbt, to treat Alzheimer's disease. The approval applied to people in the mild cognitive impairment or mild dementia stages, matching the population studied in the clinical trial. It added another therapy aimed at changing the course of early symptomatic disease rather than only easing particular symptoms. FDA described the evidence as showing a reduction in the rate of cognitive and functional decline. The decision was meaningful for patients and families seeking more options, while the approved label made clear that the medicine required careful selection, monitoring, and discussion of serious risks.
Donanemab is a laboratory-made antibody directed at aggregated beta amyloid, a protein that can accumulate in plaques in the brain. Before treatment, clinicians were to confirm amyloid pathology. The medicine was given by intravenous infusion about every four weeks, with each infusion lasting approximately 30 minutes. The original dosing schedule began with 700 milligrams for the first three doses and then increased to 1,400 milligrams. The label also allowed consideration of stopping treatment after imaging showed amyloid plaques had fallen to minimal levels. This made brain imaging relevant both before therapy and during decisions about its duration.
The central randomized trial enrolled 1,736 people at 277 sites in eight countries. Participants received donanemab or placebo for up to 72 weeks, and neither patients nor health professionals knew the assignment until the study ended. On several clinical scales, the treated group declined more slowly on average. On the Clinical Dementia Rating Scale–Sum of Boxes, the adjusted change was 1.72 with donanemab and 2.42 with placebo at week 76. That was a measured slowing of decline, not a cure, restoration of lost memory, or guarantee that an individual would notice the same degree of benefit. Most participants were White, limiting conclusions about differences among racial groups.
Safety was a central part of the approval. Amyloid-related imaging abnormalities, known as ARIA, can involve temporary brain swelling or areas of bleeding and are often found on MRI before symptoms appear. Serious and life-threatening events can occur, and risk is higher for people with two copies of the ApoE e4 variant. The original label called for a recent brain MRI before treatment and additional monitoring during therapy. Headache and infusion reactions were also reported. July 2 therefore marked an advance with important boundaries: a new treatment for a defined early-stage population, supported by evidence of slower decline, accompanied by imaging, genetic-risk discussion, and clinical oversight needed to balance possible benefit against harm.
Kisunla was studied in people with confirmed amyloid pathology and early symptomatic disease. The approval did not cover every stage or cause of dementia.
The antibody targets aggregated beta amyloid and lowers plaque levels. Removing plaque is a biological effect; the clinical goal was slower decline in thinking and daily function.
Trial participants declined on both treatment and placebo. The difference between groups showed a slowing of progression, not reversal of Alzheimer's disease.
ARIA can include brain swelling and small areas of bleeding. MRI monitoring and attention to symptoms were essential parts of safe use.
The approval expanded a new class of disease-modifying treatments. It also increased the need for infusion capacity, imaging access, and careful patient counseling.
Long-term experience would determine how the trial results translated into routine care. Cost, eligibility, monitoring, and representation in research remained important questions.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.